These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21756819)

  • 21. Tumour biology and histopathology of neuroendocrine tumours.
    Klöppel G
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):15-31. PubMed ID: 17382263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy.
    Ciombor KK; Goldberg RM
    JAMA Oncol; 2016 Dec; 2(12):1537-1538. PubMed ID: 27684887
    [No Abstract]   [Full Text] [Related]  

  • 23. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer.
    Chung DC; Yoon SS; Lauwers GY; Patel D
    N Engl J Med; 2007 Jul; 357(3):283-91. PubMed ID: 17634464
    [No Abstract]   [Full Text] [Related]  

  • 24. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells.
    Höpfner M; Sutter AP; Beck NI; Barthel B; Maaser K; Jockers-Scherübl MC; Zeitz M; Scherübl H
    Int J Cancer; 2002 Sep; 101(3):210-6. PubMed ID: 12209970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer.
    Carneiro F; Oliveira C; Suriano G; Seruca R
    J Clin Pathol; 2008 Jan; 61(1):25-30. PubMed ID: 17513507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutation in metastatic colorectal cancer.
    Tol J; Nagtegaal ID; Punt CJ
    N Engl J Med; 2009 Jul; 361(1):98-9. PubMed ID: 19571295
    [No Abstract]   [Full Text] [Related]  

  • 28. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
    Prasad V; Kaestner V; Mailankody S
    JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
    [No Abstract]   [Full Text] [Related]  

  • 29. [Standardization in pathologic diagnosis of gastrointestinal and pancreatic neuroendocrine tumors].
    Zheng J
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):793-5. PubMed ID: 21215092
    [No Abstract]   [Full Text] [Related]  

  • 30. Endocrine tumors of the gut and pancreas tumor biology and classification.
    Rindi G; Klöppel G
    Neuroendocrinology; 2004; 80 Suppl 1():12-5. PubMed ID: 15477709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
    Black PC; Brown GA; Inamoto T; Shrader M; Arora A; Siefker-Radtke AO; Adam L; Theodorescu D; Wu X; Munsell MF; Bar-Eli M; McConkey DJ; Dinney CP
    Clin Cancer Res; 2008 Mar; 14(5):1478-86. PubMed ID: 18316572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responsiveness to cetuximab without mutations in EGFR.
    Tsuchihashi Z; Khambata-Ford S; Hanna N; Jänne PA
    N Engl J Med; 2005 Jul; 353(2):208-9. PubMed ID: 16014894
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Classification of neuroendocrine tumors of the gastrointestinal tract and pancreas and its therapeutic relevance].
    Höfler H; Stier A; Schusdziarra V; Siewert JR
    Chirurg; 1997 Feb; 68(2):107-15. PubMed ID: 9156975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
    Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
    [No Abstract]   [Full Text] [Related]  

  • 36. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 38. Cetuximab in the treatment of colorectal cancer.
    Ciardiello F; De Vita F; Orditura M; Comunale D; Galizia G
    Future Oncol; 2005 Apr; 1(2):173-81. PubMed ID: 16555987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Case n(o) 6: Signet ring cell intramucosal carcinoma in hereditary diffuse gastric cancer with mutated CDH1 gene].
    Svrcek M
    Ann Pathol; 2011 Oct; 31(5):381-4. PubMed ID: 21982246
    [No Abstract]   [Full Text] [Related]  

  • 40. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.